Pay in 4 interest-free payments of $6.48 Learn more
Ships within 48 hours · Estimated delivery Sep 4 - Sep 9
and a control group of people who continued use of non-GLP-1 receptor agonist antihyperglycemics, defined as usual care (n = 1,203,097)
These often improve as the body adjusts, but if symptoms worsen or persist, medical advice should be sought promptly
(PubMed) Thompson PA, Ashbeck EL, Roe DJ, et al
The authors of the study concluded that the GLP-1 receptor agonist lixisenatide had a three-point beneficial effect, when compared with placebo, in the change over a 12-month period from a baseline value of approximately 15 points on a 132-point scale measuring motor disability. The active arm improved 0.04 points in the lixisenatide group and worsened 3.04 points in the placebo group
Expert Care and Consultation At IUVENTUS, you are part of a community that values your long-term health
US$ 28.66
US$ 22.82
US$ 28.93
US$ 25.53
US$ 26.78
US$ 24.11
